Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab.

Tjalf ZiemssenMarie GrothBenjamin EttleTobias Bopp

Published in: Vaccines (2022)

Presence of T-cell response and increase in levels of neutralizing antibodies, although less pronounced compared to controls, suggest that MS patients receiving ofatumumab are able to mount an immune response to SARS-CoV-2 mRNA vaccination.

Keyphrases

multiple sclerosis
sars cov
immune response
respiratory syndrome coronavirus
white matter
binding protein
dengue virus
toll like receptor
ms ms
systemic lupus erythematosus
zika virus
disease activity